Magazine article Drug Topics

New Products

Magazine article Drug Topics

New Products

Article excerpt



New drugs

Forest Laboratories' Teflaro (ceftaroline fosamil), a broad-spectrum bactericidal Cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by FDA for treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA). (www.

Alcon's TobraDex ST (tobramycin and dexamethasone 0.3%/0.05% ophthalmic suspension) is available for the treatment of steroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or risk of infection exists. ( / 800-757-9195)

FDA approved Axlron (testosterone topical solution), from Eli Lilly and Acrux Pharma for replacement therapy in men aged >18 years for conditions associated with a deficiency or absence of endogenous testosterone, ( / 800-545-5979)

Santarus' Cycloset (bromocriptine mesylate) tablets [1], a dopamine receptor agonist, approved by FDA in May 2009, is available for management of type 2 diabetes in adults as an adjunct to diet and exercise, ( / 888-778-0887)

FDA approved Kombiglyze XR [2] (saxagliptin and metformin extended-release) tablets from Bristol-Myers Squibb and AstraZeneca for treatment of type 2 diabetes in adults, ( / www. / 800-721-5072)

FDA approved Avanir Pharmaceuticals' Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) capsules as the first treatment for pseudobulbar affect (PBA). (

O Cu Soft's Zytaze (zinc citrate and phytase) has been approved as a medical food providing nutritional support to enhance the effectiveness of botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, or facial cosmetic procedures. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.